This review summarises important pharmacological and clinical characteristics of daratumumab in the treatment of multiple myeloma. Daratumumab is an anti-CD-38 monoclonal antibody that is indicated for the treatment of patients with relapsed multiple myeloma either as monotherapy or in combination with either lenalidomide and dexamethasone or bortezomib and dexamethasone.
Independent commentary has been provided by Dr Hang Quach, a Consultant Clinical and Laboratory
Haematologist at St. Vincent’s Hospital Melbourne.
and a Fellow of The University of Melbourne
Please login below to download this issue (PDF)